5734-64-5Relevant articles and documents
A novel benzoyl pyrimidine urea compound and its preparation and use (by machine translation)
-
Paragraph 0058; 0059; 0060; 0062; 0065, (2019/01/06)
The invention provides a benzoyl pyrimidine urea compound, of formula I or formula II structure shown. The present invention provides benzoyl pyrimidine urea compound has excellent armyworm killing, mosquito killing and broad-spectrum antifungal activity. The experimental result shows, the present invention provides benzoyl pyrimidine urea compound in 0.5 μg mL- 1 Sliding surface of larvae activity can be up to 100%, in the 0.25μg mL- 1 Sliding surface of larvae activity can be up to 100%. In the 50 μg mL- 1 When, demonstrated broad-spectrum antifungal activity, and to the cabbage in vitro blade has a certain protective effect. And low toxicity to fish, LC to the zebra fish50 Are respectively 378.387 mg L- 1 , 21.668 Mg L- 1 . Can be used to prepare insecticidal, anti-plant-pathogenic fungi pesticide application. (by machine translation)
2-amino-6-methoxypyrimidine-4-ol preparation process
-
Paragraph 0005; 0027; 0028, (2017/08/29)
The invention discloses a 2-amino-6-methoxypyrimidine-4-ol synthesis process. 4,6-dichloropyrimidine-2-amine is used as a starting material to obtain 2-amino-6-methoxypyrimidine-4-ol through a three-step reaction which includes nucleophilic substitution, electrophilic substitution and catalytic hydrogenation. The synthesis method has advantages of cheapness and easiness in acquisition of raw materials, mild operation conditions, simplicity, convenience and feasibility in aftertreatment and suitableness for industrial application.
DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF
-
Page/Page column 64, (2015/02/25)
The present invention refers to compounds of formula (I): as well as to a method for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of conditions associated with the alteration of the activity of β-galactosidase, specially galactosidase beta-1 or GLB1, including GM1 gangliosidoses and Morquio syndrome, type B.